{
  "id": 8803283,
  "title": "Australia’s Telix agrees to buy Germany’s ITM Isotope for $1.65 bln",
  "url": "https://urgent.news/2026/09/20/australias-telix-agrees-to-buy-germanys-itm-isotope-for-1-65-bln",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-20T23:48:10.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/australias-telix-agrees-to-buy-germanys-itm-isotope-for-165-bln-4908202"
  },
  "original_language": "en",
  "account": "Australian pharmaceutical company Telix Pharmaceuticals has reached an agreement to buy German radiopharmaceuticals firm ITM Isotope Technologies for a substantial upfront payment of $1.65 billion. This acquisition aims to bolster Telix's position within the radiopharmaceutical supply chain. In the deal, Telix will invest approximately $1.25 billion in its shares, while assuming $302 million of ITM's existing net debt and other transaction-related expenses. As a result of this agreement, ITM shareholders will receive 105.8 million Telix shares, allowing Telix shareholders to own around 76.3% of the merged company.\n\nITM Isotope Technologies, based in Munich, supplies therapeutic radioisotopes like lutetium-177, actinium-225, and terbium-161, and operates a global distribution network across more than 65 countries. The company generated $273 million in revenue in 2025, reflecting a compound annual growth rate of 40% since 2021. One of ITM's notable drug candidates, ITM-11, a treatment for gastroenteropancreatic neuroendocrine tumors, recently completed a successful Phase 3 trial. The transaction between Telix and ITM is expected to finalize by the end of 2026, contingent on shareholder and regulatory approvals.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}